TransMedics Group, Inc.
Rank #282HypergrowthTMDX · Nasdaq · Healthcare
TransMedics Group, Inc. (TMDX) — Rank #282 by gross profitability (GP/assets 0.25) · ROE 36.7% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001756262 · all metrics point-in-time as of the filing date.
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Show moreShow less
The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- transmedics.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-27 | 2022-12-31filed 2023-02-27 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 488.9 | 337.2 | 394.8 | 201.2 |
| Short-term investments | — | — | — | — |
| Accounts receivable | 84.3 | 97.7 | 63.6 | 27.6 |
| Inventory | 48.9 | 46.6 | 44.2 | 20.6 |
| Total current assets | 637.8 | 497.2 | 510.7 | 252.3 |
| Property, plant & equipment, net | 327.7 | 286.0 | 173.9 | 19.2 |
| Goodwill | 11.5 | 11.5 | 12.0 | — |
| Intangible assets (excl. goodwill) | 1.9 | 2.2 | 2.4 | — |
| Total assets | 1,068.4 | 804.1 | 706.0 | 277.1 |
| Liabilities | ||||
| Accounts payable | 10.4 | 10.3 | 12.7 | 3.3 |
| Deferred revenue | 2.9 | 1.7 | 2.0 | 0.2 |
| Total current liabilities | 89.3 | 59.9 | 54.9 | 23.7 |
| Total debt | 10.0 | — | — | 58.7 |
| Total liabilities | 595.3 | 575.5 | 568.8 | 89.8 |
| Equity | ||||
| Retained earnings | (278.0) | (468.2) | (503.7) | (478.7) |
| Total shareholders' equity | 473.1 | 228.6 | 137.2 | 187.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?